Johnson & Johnson announced data from the Phase 3 MajesTEC-3 trial showing that combining TECVAYLI with DARZALEX FASPRO significantly improves survival in relapsed or refractory multiple myeloma patients. About 87% of treated patients had mortality risks comparable to the general population, with a 90% reduction in disease progression risk compared to standard care. The combination nearly quadrupled median overall survival versus standard treatments, indicating potential for durable long-term disease control. Ongoing follow-up will confirm if these promising model-based survival predictions hold true.
Johnson & Johnson shares show steady interest on Pluang, with 84% of orders to buy and a slight 0.41% price increase. As of Sep 23, 2026 21:03 WIB, JNJ trades at USD 270.30, near its 52-week high of USD 278.43, reflecting ongoing investor confidence.
